Imagine if a computer could instantly read a complex heart scan that usually takes a human expert hours to analyze. It's like having an automated assistant that sorts through hundreds of images to find exactly where the heart is struggling. This removes the guesswork and long waiting lists for patients needing critical heart checks.
Cardiac Magnetic Resonance (CMR) is the gold standard for heart diagnosis but is hindered by a severe shortage of experts and high human error rates. This leads to long patient queues and millions of misdiagnosed deaths annually.
An upgraded clinical software, AI4CMR.Plus, that automatically processes CINE sequences to assess heart function and structure.
If you are a diagnostic center dealing with long queues and a scarcity of CMR experts (only 0.06-3 per 1 million Europeans) — this project developed AI4CMR.Plus that automates heart function assessment to increase patient throughput.
If you are a software provider dealing with fragmented imaging tools — this project developed a cloud-based, interoperable software that automates the analysis of over 300 contracting heart images.
If you are a public health authority dealing with the €54 billion healthcare cost of cardiovascular disease in the EU — this project developed a tool to reduce the 85% observer variability in heart scans.
Based on available project data, specific pricing details for AI4CMR.Plus are not provided, though it is positioned for a 2025 market launch.
Yes, the software is designed to be cloud-based and agnostic, aiming to democratize CMR diagnosis and make it a routine, scalable gold-standard tool.
The project data mentions that the company has obtained a patent, though full licensing terms are not detailed.
The project targets a full market launch for the upgraded AI4CMR.Plus version in 2025.
The software is developed to be fully agnostic and interoperable, facilitating integration into existing clinical workflows.
The project is led by a single Portuguese SME, AI4MedImaging Medical Solutions SA. This lean structure indicates a high level of internal control and agility, with 100% industry participation, focusing on the rapid transition from a validated MVP to a commercial product.
Contact AI4MedImaging Medical Solutions SA in Portugal
Contact us to explore licensing opportunities for AI-driven cardiac diagnostics.
